Last reviewed · How we verify
Intradermal avotermin
At a glance
| Generic name | Intradermal avotermin |
|---|---|
| Also known as | Juvista, RN1001, TGF beta 3 |
| Sponsor | Renovo |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Secretome TGF Beta 3 (NA)
- Juvista in Scar Revision Surgery of Disfiguring Scars (PHASE3)
- A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo (PHASE1)
- Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects (PHASE1, PHASE2)
- Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites (PHASE2)
- Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista) (PHASE1)
- Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista) (PHASE1, PHASE2)
- Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intradermal avotermin CI brief — competitive landscape report
- Intradermal avotermin updates RSS · CI watch RSS
- Renovo portfolio CI